Polycystic Ovarian Syndrome Market

Polycystic Ovary Syndrome (PCOS) Market Overview

The global polycystic ovary syndrome (PCOS) market size, valued at USD 3.85 billion in 2024, is projected to reach USD 4.0 billion in 2025 and USD 5.82 billion by 2035, representing a CAGR of 3.8% during the forecast period.

To learn more about this report, request a free sample copy

Polycystic Ovary Syndrome (PCOS) Market: In Summary

• According to World Health Organization, as of 2025, around 6-13% of the reproductive-age women are having polycystic ovary syndrome and up to 70% of the women with PCOS remain undiagnosed.
• The global polycystic ovary syndrome market size is projected to reach USD 4.0 billion in 2025 and USD 5.82 billion by 2035, representing a CAGR of 3.8% during the forecast period.
• North America is dominating the market by holding 61.4% share of the polycystic ovary syndrome treatment market.
• There are no FDA approved drug for PCOS; a number of drugs are used off-label for treatment of PCOS symptoms including oral contraceptives, metformin, and eflornithine.
• As of 2025, the ongoing clinical studies for PCOS symptoms management and treatment focus on new therapeutic modality, including androgens, insulin resistance and associated symptoms.
• Some examples of the drug candidates that are currently being explored for PCOS management include GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
• Currently, more than 40 industrial and non-industrial players are engaged in the development of drugs for polycystic ovary syndrome.

The market for polycystic ovary syndrome treatment is rapidly growing driven by the increasing incidence across the globe. It is a hormonal disorder also known as hormonal PCOS that affect women specifically of reproductive age. According to World Health Organization, as of 2025, around 6-13% of the reproductive-age women are having polycystic ovary syndrome and up to 70% of the women with PCOS remain undiagnosed. The condition often causes cysts inside the ovaries, over secretion of androgens, irregular periods and infertility.

As of now, there is no permanent cure or treatment available for PCOS, however symptoms can be managed with medications and lifestyle changes. Currently, there is wide range of drugs available that helps to manage symptoms associated with polycystic ovary syndrome. Some of the notable drugs as Actos^® (developed by Takeda, based in Japan), Avandia^® (developed by GlaxoSmithKline, based in UK), Victoza^® (developed by Novo Nordisk, based in Denmark), and Xenical^® (developed by Roche, based in Switzerland).

Majority of these marketed drugs belongs to medicinal drug class, such as oral contraceptives, antiandrogens, insulin-sensitizing agent, antidepressant, and anti-obesity drugs. In order to manage symptoms more efficiently, several industrial players are creating combinational drugs and exploring various drug candidates to treat PCOS.

As of 2025, the ongoing clinical studies for PCOS symptoms management and treatment focus on new therapeutic modality, including androgens, insulin resistance and associated symptoms. Some examples of the drug candidates that are currently being explored for PCOS management include GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors. It is worth noting that PCOS symptom management currently remains the cornerstone for these industrial players.

Polycystic Ovary Syndrome (PCOS) Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 4.0 Billion
Market Size 2035	USD 5.82 Billion
CAGR (Till 2035)	3.8%

One of the key objectives of the polycystic ovary syndrome (PCOS) market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of drug class, route of administration, geographical regions and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three polycystic ovary syndrome (PCOS) market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

A patient with polycystic ovary syndrome may also suffer from weight gain and insulin resistance. Since multiple symptoms are associated with PCOS, market players are increasing their strategic initiatives to explore the multitude of drug classes, which is expected to be a key driver for the market.

Recent Developments in Polycystic Ovary Syndrome (PCOS) Market

Several recent developments have taken place in the treatment of polycystic ovary syndrome, and we outline some of these below.

• In March 2025, Eli Lily launched Mounjaro® (a weight loss drug) in India. It is a first-in-class dual GLP-1 and GIP receptor agonist for weight loss and diabetes management. This drug also helps to manage symptoms associated with obesity, including sleep apnea and polycystic ovary syndrome.
• In January 2025, Celmatix Therapeutic announced its latest drug program, a novel Jun-N-terminal kinase (JNK) inhibitor that target inflammation and pain. This newly launched therapeutic drug candidate which is developed by using DNA-Encoded Chemistry Technology (DEC-Tec) platform at the Center for Drug Discovery, Baylor College of Medicine (BCM) is aiming to address the unmet medical need for a wide range of women’s health conditions, such as endometriosis, ovarian aging and polycystic ovary syndrome.

Polycystic Ovary Syndrome (PCOS) Market Segmentation Insights

The market report provides comprehensive information on polycystic ovary syndrome drug developers who are currently active across various segments of the industry as mentioned in the table below.

Polycystic Ovary Syndrome (PCOS) Market: Market Segmentation

Market Segmentations	Details
Type of Drug Class	Insulin-Sensitizing Agents Oral Contraceptives Anti-Androgens Anti-Obesity
Route of Administration	Oral Subcutaneous Intravenous Others
Type of Surgery	Ovarian Wedge Resection Laparoscopic Ovarian Drilling
Distribution Channel	Hospital Pharmacy Drug Store and Retail Pharmacy Online Providers
Geographical Regions	North America Europe Asia-Pacific Middle East and North Africa Latin America
Market in North America	US Canada Mexico
Market in Europe	France Germany Italy Spain UK Rest of Europe
Market in Asia-Pacific	China India Japan South Korea Rest of the Asia-Pacific
Market in Middle East and North Africa	Egypt Saudi Arabia United Arab Emirates
Market in Latin America	Argentina Brazil

Polycystic Ovary Syndrome (PCOS) Market Share Insights

Market Share by Type of Drug Class: Insulin-Sensitizing Agents Holds Largest Share

• Based on the drug class, the global market is segmented into insulin-sensitizing agents, oral contraceptives, anti-androgens and anti-obesity. According to the polycystic ovary syndrome (PCOS) market report, currently insulin-sensitizing agents segment is dominating the market, accounting for 48% share.
• Women suffering with PCOS tends to have high risk of insulin resistance and diabetes. Thus, insulin-sensitizing agent is largely used to manage blood sugar level and also to induce ovulation in women with PCOS.
• In the future, the oral contraceptives segment is anticipated to register a higher CAGR during the forecast period. This is likely due to the growing usage of oral contraceptives to manage symptoms of PCOS. Moreover, oral contraceptives are currently being explored in combination with drug class, such as metformin and Letrozole to regulate periods in women with PCOS and infertility issues.

Market Share by Route of Administration: Oral Segment Occupies Highest Share

• This segment highlights the distribution of global market across different routes of administration, such as oral, subcutaneous, intravenous and others. Currently, oral segment holds the largest share (81.4%) of polycystic ovary syndrome (PCOS) market size. This is likely to be the result of patient preferences of oral drugs due to ease of administration.
• It is worth mentioning that the oral segment is likely to register a substantial CAGR during the forecast period. Oral drugs are easy to consume and can be administered without assistance from healthcare experts, which is likely to fuel its demand.

Market Share by Type of Surgery: Laparoscopic Ovarian Drilling Segment Holds the Highest Share

• This segment is further divided based on type of surgery into ovarian wedge resection and laparoscopic ovarian drilling. Based on the polycystic ovary syndrome (PCOS) market analysis, the laparoscopic ovarian drilling segment holds the largest share (nearly 70%) of the market. Laparoscopic ovarian drilling is widely applicable when therapeutics drugs are inefficient to manage PCOS and patient in fertility challenges.
• However, in future, the ovarian wedge resection segment is likely to show lucrative growth, anticipated to register a higher CAGR during the forecast period. This surgical procedure is increasingly gaining attention to remove cysts from the ovaries to promote ovulation. Moreover, ovary resection also helps to regulate menstrual cycle in women, which is expected to drive its demand in the future.

Market Share by Distribution Channel: Hospital Pharmacy Holds the Highest Share

• Based on the type of distribution channel, the global market is bifurcated into hospital pharmacy, drug store and retail pharmacy, and online providers. Currently, hospital pharmacy segment is dominating by holding over 55% of polycystic ovary syndrome (PCOS) market share.
• Women prefer hospitals to purchase drugs to manage their PCOS condition due to the availability of experts who guide them and provide accurate prescription. Furthermore, hospital pharmacies serve as a direct distributor of drugs which further support the highest share of this segment.
• It is important to highlight here that by the growing trend of telemedicine and online prescription services; online providers’ segment is expected to register a higher CAGR during the forecast period. Additionally, online prescription services help women to adhere with prescriptions and receive consultation from physicians without visiting hospitals.

Market Share by Geographical Regions: North America is Dominating the Market

• The global market is distributed across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Currently, North America is dominating the market by holding 61.4% share of the polycystic ovary syndrome (PCOS) market.
• The increasing incidence of polycystic ovary syndrome in North America has necessitated the demand for advanced drugs to manage symptoms associated with PCOS. According to the U.S. Centers for Disease Control and Prevention (CDC), 5 million women in the US have PCOS. Additionally, the presence of robust industrial players who are currently investigating wide range of drugs to treat patients with PCOS is likely to fuel the market growth in this region.
• In Asia-Pacific, the market for polycystic ovary syndrome is expected to register a higher CAGR during the forecast period. The high prevalence of polycystic ovary syndrome patients in Asian countries, along with growing awareness and improved healthcare access has led to an increase in diagnosis rates, boosting the demand for PCOS managing drugs.

Polycystic Ovary Syndrome (PCOS) Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Available
Key Polycystic Ovary Syndrome Companies Profiled	AbbVie (US) Bayer (Germany) GlaxoSmithKline (UK) Lupin Pharmaceuticals (India) Merck (US) Pfizer (US) Takeda (Japan) Teva Pharmaceuticals (Israel) (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Polycystic Ovary Syndrome Market Major Takeaways

The “Polycystic Ovary Syndrome (PCOS) Market: Industry Trends and Global Forecasts, till 2035” report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for PCOS drug developers. The market research report lays emphasis on the polycystic ovarian syndrome drugs that are being developed. Key takeaways of the market report are briefly discussed below.

Polycystic Ovary Syndrome (PCOS) Market Competitive Landscape

The rising concern of polycystic ovary syndrome, growing focus on women health and lack of approved drugs makes this market highly attractive. However, currently not more than 40 industrial and non-industrial players are engaged in the development of drugs for polycystic ovary syndrome.

Notably, 70% of the industrial players are very large firms. It is worth noting that these industrial players are widely emphasizing symptomatic treatment of polycystic ovary syndrome. Some of the big pharmaceutical companies like AstraZeneca have also moved out of this space. Majority of the industry players developing drugs for treatment of PCOS, instead of the symptoms, are small drug developers like Fujian Shengdi Pharmaceutical (China), Kindex Pharmaceuticals (US), Spruce Biosciences (US), Oxolife (Spain) and Organon (US).

A few dietary supplements developers are also being evaluating their products for the treatment of PCOS. Some companies with clinical stage products include Lo.Li.Pharma (Italy) and Wellizen (Australia).

Polycystic Ovary Syndrome (PCOS) Market Size Analysis

In 2025, the market size for polycystic ovary syndrome treatment is estimated at USD 4.0 billion and is projected to reach USD 5.82 billion by 2035, representing a CAGR of 3.8% during the forecast period. This growth is likely to be the result of the growing prevalence of polycystic ovary syndrome and demand for advanced treatment to manage symptoms of PCOS.

In terms of drug class, insulin-sensitizing agents are currently dominating the market driven by the rising adoption by healthcare experts to manage PCOS symptoms in their patients.

Polycystic Ovary Syndrome (PCOS) Market: Key Drivers

Several factors that are propelling the market includes, rising prevalence of polycystic ovary syndrome in reproductive-age women, and growing awareness among women to importance of diagnosing. Improved healthcare accessibility, particularly in emerging economies, coupled with favorable health policies and increased government spending on reproductive health research, is facilitating market expansion. Additionally, the growing focus on targeted drugs to cure polycystic ovary syndrome is driving interest of industrial players in this region.

Polycystic Ovary Syndrome (PCOS) Market: Key Challenges

Despite significant demand, several factors may hinder market growth. Some of these challenges are diagnostic inconsistencies due to the lack of standardized diagnostic procedures and treatment adherence issues. It is worth mentioning that PCOS management requires long-term medication and patients may find it challenging to continue medicine for longer. Moreover, current therapeutic options primarily address symptoms rather than underlying causes of PCOS, creating a significant unmet medical need for comprehensive treatment solutions.

Polycystic Ovary Syndrome (PCOS) Market Trends

Some of the notable trends that are driving the market includes, potential clinical candidates with targeted drugs and combination therapies approach. Currently, pharmaceutical companies are actively developing novel compounds targeting specific pathophysiological mechanisms of PCOS, including specialized biologics like monoclonal antibodies addressing hormonal imbalances and inflammatory pathways.

Additionally, clinical trials are increasingly evaluating combination therapeutic strategies to address the multifaceted nature of PCOS, potentially offering more comprehensive management options. Furthermore, growing recognition of the metabolic components of PCOS is driving the development of treatments targeting insulin resistance and metabolic control, expanding beyond traditional hormone-focused approaches. In addition, the incorporation of telemedicine and e-health services is transforming PCOS management by enabling remote monitoring, improving treatment adherence, and enhancing patient engagement.

Polycystic Ovary Syndrome (PCOS) Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the polycystic ovary syndrome industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary
• Market Landscape of Polycystic Ovary Syndrome Drugs Developers
• Pipeline Reviews
• Company Profiles
• KOL Analysis
• Grant Analysis
• Clinical Trial Analysis
• Patient Analysis
• Market Forecast Analysis

Frequently Asked Questions

Question 1: What is polycystic ovary syndrome?

Answer: It refers to the hormonal condition that cause cyst, hormonal imbalance and infertility in women specifically of reproductive age.

Question 2: What is the current size of the polycystic ovary syndrome market?

Answer: Currently, the global market is valued at USD 4.0 billion in 2025.

Question 3: What is the projected value for polycystic ovary syndrome industry?

Answer: The market for polycystic ovary syndrome is expected to reach USD 5.82 billion by 2035.

Question 4: What is the CAGR of polycystic ovary syndrome industry?

Answer: The global market for polycystic ovary syndrome is estimated to grow at a CAGR of 3.8% during the forecast period.

Question 5: What regions hold the highest share of the market for polycystic ovary?

Answer: North America presently accounts for the largest share of the market.

Question 6: What are the major factors of the polycystic ovary syndrome market growth?

Answer: Growing demand for polycystic ovary syndrome management drugs and increasing awareness among consequences associated with PCOS along with obesity risk are some of the key factors driving the market growth.

Question 7: Who are the leading polycystic ovary syndrome manufacturers?

Answer: AbbVie, Bayer, GlaxoSmithKline, Lupin Pharmaceuticals, Merck, Pfizer, Takeda, and Teva Pharmaceuticals.

Question 8: What is the first line drug for PCOS?

Answer: First line drug for PCOS is birth control pills, anti-obesity drugs, and insulin-sensitizing agents. These drugs are widely used to manage symptoms associated with PCOS, such as insulin resistance, and obesity.

Question 9: Which pill is best for PCOS?

Answer: Progestin-only pills or contraceptive pill is ideal to manage PCOS symptoms such as hormonal imbalances. Furthermore, metformin, and Letrozole (Femara®) can also help to stimulate ovaries for ovulation in women with PCOS.